Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer

Keyphrases

• Pancreatic Cancer 100%
• Neoantigen Vaccine 100%
• TIGIT 100%
• PD-1 Blockade 100%
• Pancreatic Ductal Adenocarcinoma 50%
• Neoantigen 40%
• Programmed Death-ligand 1 (PD-L1) 40%
• Tumor 20%
• Tumor Growth 20%
• T Cell Response 20%
• Signaling Pathway 20%
• Translational Studies 20%
• Specific T Cells 20%
• Cancer Neoantigens 20%
• Poly IC 10%
• Toll-like 10%
• T Cell Activation 10%
• Cancer Types 10%
• CDK12 10%
• Genetic Modification 10%
• Human Pancreatic Ductal Adenocarcinoma 10%
• Vaccination 10%
• Cell Tumor 10%
• Receptor Agonist 10%
• Study Support 10%
• Cancer Immunotherapy 10%
• Regulatory Mechanism 10%
• Synthetic Peptides 10%
• Therapeutic Efficacy 10%
• Tumor Regression 10%
• Immunogenic 10%
• Immune Regulation 10%
• Vaccine Response 10%
• T Cell Depletion 10%
• Antigen-specific T Cell Response 10%
• Tumor-bearing Mice 10%
• CD155 10%
• Immune Checkpoint Signaling 10%

Immunology and Microbiology

• Neoantigen 100%
• T Cell 40%
• Immunity 13%
• Polyinosinic:polycytidylic Acid 6%
• Cell Function 6%
• Agonist 6%
• Cancer Immunotherapy 6%
• Gene Mutation 6%
• Programmed Death-Ligand 1 6%
• CD155 6%
• Toll-Like Receptor 6%
• Peptides 6%